The most advanced multiomic tissue test
that delivers maximum insights from minimal tissue.1,2
Success rate of 97%
at low inputs1‡
Broad coverage
with
Medicare patients paying $0§
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Powered by Guardant Infinity™
Multiomic insights from DNA,
RNA, and epigenomics1*
Lowest sample input
with 40% fewer slides1†
NGS, next-generation sequencing.
*Median turnaround time from sample receipt to results is 11 days.2
†6 slides for Guardant360 Tissue vs 10-slide industry standard for NGS testing only.
‡With tissue input of ≥2 mm2 surface area and ≥5% tumor cellularity. Referring to DNA performance only; RNA performance may vary.
§For qualifying Medicare patients.